Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
about
Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemyIntensive care medicine research agenda on invasive fungal infection in critically ill patients.Altered Micafungin Pharmacokinetics in Intensive Care Unit PatientsIn Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal InfectionEffect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.Low Caspofungin Exposure in Patients in Intensive Care Units.Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal InfectionsCaspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.UPLC-MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units.
P2860
Q26745677-AD88E345-7D8E-4C71-BEA0-E84EB9F38A01Q30235457-738FF87F-6126-47BC-96EF-7776B300A4F1Q35860004-248FFAC5-6AEF-4477-B750-BBE1194448BBQ36571906-74855CDE-0242-4293-AF8C-3A092906B847Q37287812-C6B0F3DE-C241-403D-9E72-F8C2F05589B2Q37358623-5F41FC7F-4932-473A-AB69-216F579C2F52Q37612914-40D05A3A-3379-442E-BBD3-29CB24A8CA01Q37612946-D08986D3-3BDC-4EF6-BFB5-D9369B025840Q38382954-397FB98A-D9E9-4E48-B72C-673CD59B15DDQ38681635-20E58702-0BC9-4092-8E60-1F84502B214FQ38790740-6533BEFE-4DDE-4624-8AA2-9B88EF52E2DFQ39020129-32A8B7BF-7061-4A8D-901F-8A079322DBBFQ40100873-BB2494ED-D5E6-48A7-A684-1A2E6D61C7CEQ47749829-2D0A611F-F2AE-40F5-A606-946AECCFD4ECQ48016535-CB223E12-3E65-4703-8D67-F0A8B5058F15
P2860
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@ast
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@en
type
label
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@ast
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@en
prefLabel
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@ast
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@en
P2093
P2860
P50
P1433
P1476
Pharmacokinetic variability an ...... re unit (DALI) patients Study.
@en
P2093
Claude Martin
DALI Study authors
George Dimopoulos
Jan J De Waele
Kirsi-Maija Kaukonen
Matteo Bassetti
Philippe Montravers
Steven C Wallis
Therese Starr
P2860
P2888
P356
10.1186/S13054-015-0758-3
P50
P577
2015-02-04T00:00:00Z
P5875
P6179
1051660459